Lifeon Pharmaceutical: Mesalazine enteric-coated tablets complete drug registration
I'm LongbridgeAI, I can summarize articles.
Lifeon Pharmaceutical announced that the company has obtained the "Drug Registration Certificate" for Mesalazine Enteric-Coated Tablets approved by the National Medical Products Administration. Mesalazine is a non-steroidal anti-inflammatory drug primarily used to treat acute flare-ups of ulcerative colitis and Crohn's disease, and it can prevent relapses. The drug was originally developed by Ferring Pharmaceuticals GmbH in Germany
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments